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IMPORTANCE International studies report a decline in mortality following non–ST-elevation
myocardial infarction (NSTEMI). Whether this is due to lower baseline risk or increased
utilization of guideline-indicated treatments is unknown.
OBJECTIVE To determine whether changes in characteristics of patients with NSTEMI are
associated with improvements in outcomes.
DESIGN, SETTING, AND PARTICIPANTS Data on patients with NSTEMI in 247 hospitals in
England andWales were obtained from theMyocardial Ischaemia National Audit Project
between January 1, 2003, and June 30, 2013 (final follow-up, December 31, 2013).
EXPOSURES Baseline demographics, clinical risk (GRACE risk score), and pharmacological and
invasive coronary treatments.
MAIN OUTCOMES ANDMEASURES Adjusted all-cause 180-day postdischargemortality time
trends estimated using flexible parametric survival modeling.
RESULTS Among 389057 patients with NSTEMI (median age, 72.7 years [IQR, 61.7-81.2
years]; 63.1%men), there were 113 586 deaths (29.2%). From 2003-2004 to 2012-2013,
proportions with intermediate to high GRACE risk decreased (87.2% vs 82.0%); proportions
with lowest risk increased (4.2% vs 7.6%; P= .01 for trend). The prevalence of diabetes,
hypertension, cerebrovascular disease, chronic obstructive pulmonary disease, chronic renal
failure, previous invasive coronary strategy, and current or ex-smoking status increased
(all P < .001). Unadjusted all-cause mortality rates at 180 days decreased from 10.8% to 7.6%
(unadjusted hazard ratio [HR], 0.968 [95% CI, 0.966-0.971]; difference in absolute mortality
rate per 100 patients [AMR/100], −1.81 [95% CI, −1.95 to −1.67]). These findings were not
substantially changed when adjusted additively by baseline GRACE risk score (HR, 0.975
[95% CI, 0.972-0.977]; AMR/100, −0.18 [95% CI, −0.21 to −0.16]), sex and socioeconomic
status (HR, 0.975 [95% CI, 0.973-0.978]; difference in AMR/100, −0.24 [95% CI, −0.27 to
−0.21]), comorbidities (HR, 0.973 [95% CI, 0.970-0.976]; difference in AMR/100, −0.44
[95% CI, −0.49 to −0.39]), and pharmacological therapies (HR, 0.972 [95% CI,
0.964-0.980]; difference in AMR/100, −0.53 [95% CI, −0.70 to −0.36]). However, the
direction of association was reversed after further adjustment for use of an invasive coronary
strategy (HR, 1.02 [95% CI, 1.01-1.03]; difference in AMR/100, 0.59 [95% CI, 0.33-0.86]),
which was associated with a relative decrease in mortality of 46.1% (95% CI, 38.9%-52.0%).
CONCLUSIONS AND RELEVANCE Among patients hospitalized with NSTEMI in England and
Wales, improvements in all-cause mortality were observed between 2003 and 2013. This was
significantly associated with use of an invasive coronary strategy and not entirely related to a
decline in baseline clinical risk or increased use of pharmacological therapies.
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T here has been a global decline in the rates of death fol-lowing acute coronary syndrome; however, the extenttowhich this is due to use of guideline-indicated treat-
ments for management of non–ST-elevation myocardial in-
farction (NSTEMI) is not known.1-3 Randomized clinical trials
provide evidence for reductions inmorbidity associatedwith
useofpharmacological and invasivecoronarystrategiesamong
patients hospitalized with NSTEMI.4,5 With the introduction
of troponin assays, the detection of NSTEMI of lower clinical
risk has increased, which may account for improved clinical
outcomes in this population.6,7
However, there is apaucityof contemporary studiesof suf-
ficient duration and representation from a population per-
spective that enable a detailed evaluation of the association
of baseline risk and guideline-indicated therapies with mor-
tality amongpatientswithNSTEMI.1,8-10 TheMyocardial Isch-
aemia National Audit Project (MINAP) is the only whole-
country acute coronary syndrome registry, representing all
hospitals in a single health system (the National Health Ser-
vice of England andWales) with prospective collection of de-
tailed information about quality of care and clinical out-
comes of patients for more than 15 years.11,12 Thus, MINAP
represents anopportunity toundertakephenotype- and treat-
ment-specific studies of temporal changes in clinical out-
comes forNSTEMI.Therefore,weaimedto investigatewhether
temporal improvements in 180-day mortality between 2003
and 2013 were associated with changes in patients’ baseline
clinical risk or use of guideline-indicated treatments forman-
agementofNSTEMIamongpatients in theUKNationalHealth
Service.
Methods
Data and Patients
MINAP is a comprehensive clinical database of patients hos-
pitalized with acute myocardial infarction, mandated by the
Department of Health for all hospitals in England andWales.
Data are collected prospectively at each hospital, electroni-
cally encrypted, and transferred online to a central database.
Data entry is subject to routine error checking and a manda-
tory annual data validation exercise. Mortality data were ob-
tained through linkagewithOffice forNational Statisticsdeath
records, which occurs on an annual basis. Further details of
MINAP have been published elsewhere.11
The analytical cohort was derived from all patients with
NSTEMIadmittedto1of247hospitalsbetweenJanuary1,2003,
and June30, 2013 (eFigure 1 in theSupplement). Patientswere
eligible for the study if theywere aged 18 years or olderwith a
final diagnosis of NSTEMI. The final diagnosis was deter-
minedby local clinicians according topresentinghistory, clini-
cal examination, and the results of inpatient investigations in
keeping with the consensus document of the Joint European
Society of Cardiology and American College of Cardiology.13
Patientswho died in the hospital were excluded from the
studybecause itwasnot possible to accurately ascertain their
receipt of pharmacological therapies. Furthermore, patients
withmissingpostdischargemortalitydatawereexcluded from
theanalysis.A sensitivity analysiswas conducted toassess the
statistical effect of excluding those who died in the hospital
(eAppendix 1 and eTables 2-4 in the Supplement).
Patient-level data included baseline Global Registry of
AcuteCoronaryEvents (GRACE) risk score (including age, car-
diac arrest, ST-segment deviation, elevated enzyme levels,
systolic blood pressure, heart rate, loop diuretic [substituted
forKillip class], andcreatinine), patientdemographics (sex, in-
dex ofmultiple deprivation), comorbidities (history of diabe-
tes, smoking, coronary heart disease, hypertension, myocar-
dial infarction, angina, peripheral vascular disease,
cerebrovascular disease, chronic obstructive pulmonary dis-
easeorasthma,chronic renal failure [definedascreatinine level
chronically>200μmol/L {>2.26mg/dL}], congestiveheart fail-
ure, previouspercutaneous coronary intervention [PCI], coro-
nary artery bypass graft [CABG] surgery, and elevated choles-
terol level [defined as an elevation of serum cholesterol
requiringdietary or drug treatment]), pharmacological thera-
pies at discharge (aspirin, β-blockers, statins, angiotensin-
converting enzyme inhibitors or angiotensin receptor block-
ers, P2Y12 inhibitors, or aldosterone antagonists), use of an
invasivecoronarystrategy (coronaryangiography,PCI,orCABG
surgery), and mortality (through linkage to the Office for
National Statistics).
Ethical Approval
The National Institute for Cardiovascular Outcomes Re-
search, which includes theMINAP database, has support un-
der section 251 of the National Health Service Act of 2006 to
use patient information for medical research without in-
formedconsent. Ethical approvalwasnot requiredunder cur-
rent National Health Service research governance arrange-
ments.
Statistical Analyses
Baseline characteristics were described using numbers and
percentages for categorical data and means and standard
deviations or medians and interquartile ranges for normally
and nonnormally distributed continuous variables. For each
patient, the probability of 180-day all-cause mortality after
discharge was calculated using the GRACE risk score (range,
Key Points
Question Are temporal changes in clinical factors and therapeutic
strategies associated with improvements in survival following
non–ST-elevationmyocardial infarction?
Findings In this prospective cohort study of 389057 patients
from 2003 to 2013, patient clinical risk decreased while use of
guideline-indicated care increased. There was a significant
decrease in 180-day all-cause mortality from 10.8% to 7.6% that
was associated with increased use of an invasive coronary strategy
after adjustment for changes in clinical risk and pharmacological
therapies.
Meaning Invasive management may have been a contributor to
declining mortality due to non–ST-elevationmyocardial infarction
between 2003 and 2013.
Research Original Investigation Trends in Patient vs Therapeutic Strategies AssociatedWith NSTEMI Mortality, 2003-2013
1074 JAMA September 13, 2016 Volume 316, Number 10 (Reprinted) jama.com
Downloaded From: http://jama.jamanetwork.com/ by a University of Leeds User  on 09/30/2016
Copyright 2016 American Medical Association. All rights reserved.
5-254.8; higher scores indicate greater risk).14,15 Given inter-
national guidelines, patients were categorized according to
their risk of 180-day mortality using their GRACE risk score
into lowest risk (<70), low risk (70-87), and intermediate to
high risk (≥88).5,16 Temporal trends of patient and treatment
characteristics were summarized by comparing data from
the start of the study (2003-2004) to the end of the study
(2012-2013) using χ2 tests, t tests, and Wilcoxon rank sum
tests. An ordered logistic regression model was fitted to
determine the temporal trend in GRACE risk score category
for each year of the study period, and results are presented
as odds ratios.
A series of Royston-Parmar flexible parametric survival
models17 were fitted to determine the extent to which phar-
macological treatments andan invasive coronary strategy (de-
fined as coronary angiography, PCI, or CABG surgery) ex-
plained the association between baseline risk and survival
trends. Flexible parametric survival models were selected in
favor of Cox regression models to overcome violation of the
proportional hazards assumption. Initially, a bivariablemodel
was fitted todetermine theoverall temporal trendbyyear. Sub-
sequently, the statistical effect of the GRACE risk score, co-
morbidity, pharmacological therapies at discharge, and an in-
vasive coronary strategy on the yearly temporal trend was
determined by incrementally adding these data to themodel
(see eTable 5 in the Supplement for sensitivity of the model
to order of model building).
Multiple imputationbychainedequationswasused topro-
duce 10 imputed data sets to minimize bias caused by miss-
ing data (eAppendix 2 and eTables 6-8 in the Supplement).
Pooled estimates and accompanying 95% confidence inter-
vals were generated according to Rubin’s rules.18 Improve-
ments inmodel fit at each stageweredeterminedbyminimiz-
ing theAkaike informationcriterionandBayesian information
criterion ranges across all 10 imputations. The scale (propor-
tional hazards, proportional odds, or normal) and complexity
(number of degrees of freedom) for flexible parametric sur-
vivalmodelswere checkedon the fullmultivariablemodel for
each imputation (eTable 9 in the Supplement). To assess the
potential statistical effect of clustering of patientswithinhos-
pitals, a sensitivity analysis was conducted comparing esti-
mates from a Cox model with and without the inclusion of a
shared frailty term (eAppendix 3 and eTable 10 in the Supple-
ment). To assess the potential for selection bias, an instru-
mental variable analysis with hospital rates of coronary angi-
ography served to approximate a random assignment of
patients to regional treatmentgroups thatdiffered in their like-
lihood of receiving an invasive coronary strategy (eAppendix
4 and eTables 11 and 12 in the Supplement). In addition, ame-
diation analysis was conducted to determine the proportion
of survival trends that were mediated by pharmacological
therapies oruseof an invasive coronary strategy in turn,while
adjusting for confounding variables (eAppendix 5 and eFig-
ures 3 and 4 in the Supplement).
All testswere2-sided, andstatistical significancewas con-
sidered P < .05. Statistical analyses were performed in Stata
version 14 (http://www.stata.com/) andRversion 3.1.2 (https:
//cran.r-project.org/).
Results
The analytical cohort (n = 389057) was drawn from 441945
patients with NSTEMI admitted to 1 of 247 hospitals between
January 1, 2003, and June 30, 2013 (eFigure 1 in the Supple-
ment). A total of 31 321 patients (7.1%) who died in the hospi-
tal and 21 567 patients (4.9%)who hadmissing postdischarge
mortality data were excluded from the analysis. The median
follow-up timewas 2.3 years (maximum, 8.4 years; 1 079044
person-years). Themedianage for theNSTEMIcohortwas72.7
years (interquartile range, 61.7-81.2 years); 63.1% were male.
Typically, individuals had high comorbidity: more than half
hadhypertensionorwereacurrentorex-smokerandmorethan
aquarter haddiabetes, angina, or previousmyocardial infarc-
tion (Table 1). Overall, 82.9% had an intermediate to high
GRACE risk score, 9.7%had a lowGRACE risk score, and 7.4%
had a lowest GRACE risk score. During the full follow-up pe-
riod, therewere 113 586 deaths (29.2%) corresponding to 10.5
deaths per 100 person-years. At 180 days after hospital dis-
charge, there had been 37 236 deaths (9.6%).
Temporal Trends in Clinical Characteristics
Temporal trends in baseline clinical characteristics are shown
in Table 1. Over the study period, the proportion of patients
withNSTEMIwhohaddiabetes, hypertension, cerebrovascu-
lar disease, chronic obstructivepulmonarydiseaseor asthma,
chronic renal failure, previous PCI, previousCABGsurgery, or
current or ex-smoking status increased (all P<.001 for trend).
In contrast, the proportion of patientswith previousmyocar-
dial infarction, angina, peripheral vascular disease, and con-
gestiveheart failuredecreased (allP<.001 for trend).Therewas
a reduction in theproportionofpatientswithNSTEMIwhohad
an initial diagnosis of chest pain of uncertain cause (21.3% vs
13.4%;difference, 7.9%;95%CI, 6.9%-8.9%;P<.001 for trend)
and corresponding increase in thenumber of patientswith an
initial diagnosis of acute coronary syndromeorprobable acute
myocardial infarction (57.6%vs72.8%;difference, 15.2%;95%
CI, 14.6%-15.9%; P<.001 for trend).
Temporal Trends in GRACE Risk Score
From 2003-2004 to 2012-2013, the proportions of NSTEMI in
the intermediate to high GRACE risk category decreased
(87.2% vs 82.0%; difference, 5.2%; 95% CI, 1.78%-8.62%); the
proportions in the lowest GRACE risk category increased
(4.2% vs 7.6%; difference, 3.4%; 95% CI, −5.9% to 12.7%); and
the proportions at low risk increased (8.6% vs 10.4%; differ-
ence, 1.8%; 95% CI, −7.3% to 10.9%) (P = .01 for trend) (eFig-
ure 2 in the Supplement). During the entire study period
(2003-2013), patients were on average less likely to be at
intermediate to high GRACE risk (odds ratio, 0.96; 95% CI,
0.96-0.97 per year) (Table 2). This temporal trend remained
after adjusting for additional patient demographics, comor-
bidity, and pharmacological medications prescribed at hospi-
tal discharge. Over the study period, more patients who
underwent an invasive coronary strategy were in the inter-
mediate to high GRACE risk category (odds ratio, 1.01; 95%
CI, 1.01-1.02 per year).
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Table 1. Patient Characteristics by Year of Hospitalizationa
Characteristics
Total Cohort, 2003-2013
(N = 389 057)
2003-2004
(n = 67 441)
2012-2013
(n = 56 649)
Difference, 2012-2013 −
2003-2004 (95% CI)
Missing
Data, %
Age, median (IQR), y 72.7 (61.7-81.2) 72.8 (62.2-80.9) 72.0 (61.0-81.0) 0.80 (0.56 to 1.04) 0.2
Male, No. (%) 244 837 (63.1) 41 873 (62.3) 36 262 (64.1) 1.80 (1.12-2.48) 0.2
Deprivation, median (IQR), IMD scoreb 18.2 (10.6-31.5) 18.9 (11.0-32.8) 17.9 (10.4-31.4) 0.99 (0.77-1.21) 7.8
Systolic blood pressure, mean (SD), mm Hg 142.5 (28.4) 143.8 (29.6) 141.8 (27.1) −2.01 (−2.38 to −1.65) 17.1
Heart rate, mean (SD), /min 83.3 (23.8) 84.6 (25.2) 81.2 (21.6) −3.38 (−3.68 to −3.08) 16.9
Total cholesterol, median (IQR), mg/dL 185.6 (150.8-224.3) 193.4 (158.5-232.0) 177.9 (146.9-220.4) 15.08 (14.31 to 15.86) 39.5
Creatinine, median (IQR), mg/dL 1.04 (0.86-1.29) 1.20 (1.04-1.46) 0.98 (0.81-1.23) 0.22 (0.19 to 0.24) 42.6
Medical history, No. (%)
Previous diabetes 81 469 (22.5) 9950 (20.6) 13 667 (24.5) 3.90 (2.83 to 4.97) 7.1
Current or ex-smoker 217 116 (60.3) 32 817 (55.7) 32 467 (59.8) 4.10 (3.34 to 4.86) 7.5
Family history of CHD 77 288 (31.7) 973 (37.3) 13 587 (29.5) −7.80 (−10.93 to −4.67) 37.2
Hypertension 188 503 (52.8) 23 754 (47.3) 30 063 (55.5) 8.20 (7.35 to 9.05) 8.3
Previous MI 97 002 (27.1) 14 409 (28.6) 14 017 (25.8) −2.80 (−3.83 to −1.77) 8.0
Previous angina 122 566 (34.6) 18 898 (37.8) 16 419 (30.5) −7.30 (−6.31 to −8.29) 8.9
Peripheral vascular disease 18 324 (5.3) 2787 (5.8) 2673 (5.0) −0.80 (−2.00 to 0.40) 11.5
Cerebrovascular disease 34 146 (9.8) 4311 (9.2) 5240 (9.7) 0.50 (−0.68 to 1.68) 10.6
COPD or asthma 56 708 (16.5) 7417 (15.9) 9058 (16.8) 0.90 (−0.23 to 2.03) 11.4
Chronic renal failure 21 938 (6.3) 1911 (4.0) 4161 (7.7) 3.7 (2.50 – 4.90) 10.4
Congestive heart failure 24 529 (7.0) 3835 (8.0) 3603 (6.7) −1.30 (−2.48 to −0.12) 10.4
Previous PCI 32 663 (9.3) 2678 (5.7) 6642 (12.3) 6.60 (5.42 to 7.78) 10.1
Previous CABG surgery 27 637 (7.9) 2964 (6.2) 4793 (8.9) 2.70 (1.52 to 3.88) 9.8
Preadmission medications, No. (%)c
Aspirin 130 185 (55.0) 19 310 (42.6) 16 915 (71.6) 29.00 (28.03 to 29.97) 7.6
β-Blocker 90 045 (32.5) 593 (50.1) 16 935 (32.7) −17.40 (−21.49 to −13.31) 26.5
Statin 137 644 (48.2) 680 (57.6) 26 290 (48.4) −9.20 (−12.96 to −5.44) 29
ACE inhibitor or ARB 113 345 (41.0) 588 (49.6) 22 025 (42.4) −7.20 (−11.29 to −3.11) 28.9
P2Y12 inhibitor 24 180 (14.5) 0 7602 (14.3) 57.3
Warfarin 21 544 (6.7) 3045 (7.4) 3168 (6.3) −1.10 (−2.36 to 0.16) 17.9
Discharge medications, No. (%)c
Aspirin 301 639 (97.1) 55 738 (95.9) 42 876 (98.4) 2.50 (2.30 to 2.70) 7.8
β-Blocker 244 962 (91.5) 41 066 (85.4) 37 610 (95.4) 10.00 (9.60 to 10.40) 8.3
Statin 297 045 (94.1) 51 834 (89.0) 42 541 (96.6) 7.60 (7.28 to 7.93) 9.1
ACE inhibitor or ARB 251 406 (87.6) 43 804 (81.1) 36 709 (92.6) 11.50 (11.05 to 11.95) 8.6
P2Y12 inhibitor 127 356 (93.1) 0 38 854 (94.9) 54.9
Aldosterone antagonist 9702 (11.9) 0 3266 (13.7) 58.8
Admission diagnosis, No. (%)
ACS or probable MI 252 456 (64.9) 38 843 (57.6) 41 243 (72.8) 15.20 (14.55 to 15.85)
Chest pain, unknown cause 64 677 (16.6) 14 326 (21.3) 7563 (13.4) −7.90 (−8.92 to −6.88) 0.01
Other 71 876 (18.5) 14 256 (21.1) 7843 (13.8) −7.30 (−8.32 to −6.28)
GRACE risk score category, No. (%)d
Lowest (<70) 11 192 (7.4) 18 (4.2) 2496 (7.6) 3.40 (−5.92 to 12.72)
Low (70-87) 14 695 (9.7) 37 (8.6) 3401 (10.4) 1.80 (−7.29 to 10.89) 61.2
Intermediate to high (≥88) 125 213 (82.9) 374 (87.2) 26 847 (82.0) −5.20 (−8.62 to −1.78)
Use of an invasive coronary strategye 214 302 (63.3) 22 056 (42.7) 40 771 (78.6) 35.90 (35.14 to 36.66) 13.0
Abbreviations: ACE, angiotensin-converting enzyme; ACS, acute coronary
syndrome; ARB, angiotensin receptor blocker; CABG, coronary artery bypass
graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary
disease; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous
coronary intervention.
SI conversions: To convert total cholesterol to millimoles per liter, multiply by
0.0259. To convert creatinine to micromoles per liter, multiply by 88.4.
a P values for linear trend across all study years (2003-2013) were all significant
at the.01 level.
b Index of Multiple Deprivation (IMD) scores range from0.59 to 86.36; higher
scores indicate greater deprivation.
c Only patients eligible to receive treatments were included in the denominator.
dGlobal Registry of Acute Coronary Events (GRACE) risk scores range from 5 to
258.4.
e Coronary angiography, PCI, or CABG surgery.
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Temporal Trends in Guideline-Indicated Treatments
The use of aspirin (95.9%vs 98.4%; difference, 2.5%; 95%CI,
2.3%-2.7%;P<.001 for trend), β-blockers (85.4%vs95.4%;dif-
ference, 10%; 95% CI, 9.6%-10.4%; P<.001 for trend), statins
(89.0%vs96.6%;difference, 7.6%;95%CI, 7.3%-7.9%;P<.001
for trend), angiotensin-converting enzyme inhibitors or an-
giotensin receptor blockers (81.1%vs92.6%;difference, 11.5%;
95% CI, 11.1%-12.0%; P<.001 for trend), P2Y12 inhibitors (0%
vs 94.9%), and aldosterone antagonists (0% vs 13.7%) at dis-
charge increased (Figure 1). The use of coronary angiography,
PCI, or CABG surgery increased (P < .001) and in 2012-2013
reachedratesof71.5%,33.3%,and3.0%, respectively (Figure 1).
Aspirin, P2Y12 inhibitors, β-blockers, angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers, and stat-
inshadasignificantassociationwith improvedsurvival (eTable
1 in the Supplement).
Temporal Trends inMortality
From 2003-2004 to 2012-2013, unadjusted all-cause mortal-
ity ratesat30days followinghospitaldischargedecreased from
2.6% (95% CI, 2.5%-2.7%) to 2.0% (95% CI, 1.9%-2.1%) and at
180 days from 10.8% (95% CI, 10.5%-10.9%) to 7.6% (95% CI,
7.4%-7.8%). Over the study period, there was an absolute de-
crease in the adjusted mortality rate of 0.48 per 100 patients
(95%CI,0.25-0.72per 100), corresponding to anaverage 3.2%
relative improvement in survival per year (hazard ratio [HR],
0.968; 95% CI, 0.966-0.971). Figure 2 shows that the decline
in mortality at 30 and 180 days was greater for patients with
NSTEMIwhowere at intermediate tohighGRACE risk than for
patients at lowest and low GRACE risk. In-hospital mortality
decreased from10.9% in2003-2004 to5.0% in2012-2013 (dif-
ference, 5.9%; 95% CI, 4.8%-6.9%).
Association Between Changing Risk Profile
and ImprovedOutcomes
The magnitude of the temporal survival improvements be-
tween 2003 and 2013was similarwhen adjusted additively by
baseline GRACE risk (difference in absolute mortality rate per
100 [AMR/100],−0.18 [95%CI,−0.21 to−0.16];HR,0.975 [95%
CI, 0.972-0.977]), sex and socioeconomic status (difference in
AMR/100, −0.24 [95% CI, −0.27 to −0.21]; HR, 0.975 [95% CI,
0.973-0.978]), comorbidities (difference in AMR/100, −0.44
[95%CI,−0.49to−0.39];HR,0.973 [95%CI,0.970-0.976]), and
pharmacological therapiesprescribedathospitaldischarge (dif-
ference inAMR/100,−0.53 [95%CI, −0.70 to−0.36];HR,0.972
[95%CI, 0.964-0.980]) (Table 3). However, when use of an in-
vasive coronary strategy (coronary angiography, PCI, or CABG
surgery) was added, the temporal improvements in survival
were reversed (difference in AMR/100, 0.59 [95% CI, 0.33-
0.86]; HR, 1.02 [95% CI, 1.01-1.03]), suggesting that this vari-
able significantly accounted for at least part of the reduction in
NSTEMImortalitybetween2003and2013above thatof reduc-
ingbaseline risk, increasing comorbidities, anduseofpharma-
cological therapies.Afteraccounting foruseofan invasivecoro-
narystrategy,apparentbaselinesurvivalworsenedbyanaverage
of 2.0%per year. This result remained consistent in a sensitiv-
ity analysis whereby in-hospital deaths were included (HR,
1.020; 95%CI, 1.004-1.035) (eTable 4 in the Supplement). The
finding that the increased use of an invasive coronary strategy
was associated with temporal improvements in survival was
consistentwithmediation,which showed that 88.3% (95%CI,
55.3%-89.6%) and9.9% (95%CI, 5.6%-10.6%) of this temporal
changemaybe explained by increaseduse of an invasive coro-
narystrategyandpharmacological therapies, respectively (eAp-
pendix 5 in the Supplement).
Table 2. Relationship Between CaseMix, Comorbidities, Pharmacological Therapies at Discharge, and Invasive Coronary Strategy
and GRACE Risk Score Categorization, 2003-2013
Modela
Yearly Time Trend for Higher GRACE Score Categorization AIC and BIC Ranges Over 10 Imputed Data Sets
Odds Ratio
(95% CI)b P Value
Absolute Difference in Odds
(95% CI)c AIC Range BIC Range
Unadjusted yearly time trend 0.96 (0.96-0.97) <.001 −0.037 (−0.040 to −0.034) 489 413.2-490 512.0 489 445.8-490 544.7
Yearly time trend adjusted for
Sex and IMD 0.96 (0.96-0.970) <.001 −0.037 (−0.040 to −0.034) 479 090.7-480 143.6 479 145.1-480 198.0
Sex, IMD, and comorbiditiesd 0.96 (0.95-0.96) <.001 −0.045 (−0.050 to −0.042) 442 792.3-444 023.5 442 988-444 219.2
Sex, IMD, comorbidities,
and pharmacological therapies
at dischargee
0.98 (0.97-0.99) <.001 −0.020 (−0.028 to −0.013) 261 326.3-261 947.5 261 573.6-262 194.9
Sex, IMD, comorbidities,
pharmacological therapies
at discharge, and invasive
coronary strategyf
1.01 (1.01-1.02) .001 0.014 (0.006 to 0.021) 252 226.8-252 967.1 252 494.7-253 235.1
Abbreviations: AIC, Akaike information criterion; BIC, Bayesian information
criterion; GRACE, Global Registry of Acute Coronary Events; IMD, Index of
Multiple Deprivation.
a Ordered logistic regressionmodels performed after multiple imputation.
b The odds ratio indicates the likelihood of higher GRACE risk score
categorization.
c Absolute difference in odds of higher GRACE risk score categorization
between 2003 and 2013.
d Including history of diabetes, smoking, family history of coronary heart
disease, hypertension, myocardial infarction, angina, peripheral vascular
disease, cerebrovascular disease, chronic obstructive pulmonary disease,
chronic renal failure, congestive heart failure, percutaneous coronary
intervention, coronary artery bypass graft surgery, elevated cholesterol
(defined as elevation of serum cholesterol level requiring dietary or drug
treatment).
e Aspirin, β-blockers, statins, angiotensin-converting enzymes inhibitors or
angiotensin receptor blockers, P2Y12 inhibitors, and aldosterone antagonists.
f Coronary angiography, percutaneous coronary intervention, or coronary
artery bypass graft surgery. Age, cardiac arrest, ST-segment deviation,
elevated enzymes, systolic blood pressure, heart rate, loop diuretic, and
creatinine were not individually included in themodeling process because
they were all used in the calculation of the GRACE risk score.
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Within the instrumental variable analysis, use of an inva-
sive coronary strategy was associated with a relative de-
crease inmortality of 46.1% (95%CI, 38.9%-52.0%) (eAppen-
dix 4 in the Supplement). Furthermore, the estimate of the
indirect contribution associated with an invasive coronary
strategy through the provision of cardiac rehabilitation was
small (3.6%; 95% CI, 3.0%-3.7%).
Discussion
In this prospective observational cohort studyof themanage-
ment andoutcomeof patientswith acute coronary syndrome
using data for all hospitals in a single health care system, im-
provements insurvival followingNSTEMIwereassociatedwith
use of an invasive coronary strategy. Among nearly 400000
patients with NSTEMI hospitalized between 2003 and 2013,
the temporal reduction in baseline acute coronary syndrome
risk, increase in comorbidities, and use of guideline-
indicated pharmacological therapies did not fully explain the
relative 3.2% yearly improvement in survival. As seen in in-
ternational registries, these improvementswere significantly
and independently associated with use of an invasive coro-
nary strategy.19
International guidelines recommenduseofpharmacologi-
cal therapies and invasive coronary procedures according to
baseline clinical risk.4,5 This is a result of robust evidence from
randomized clinical trials clearly showing that early interven-
tion in moderate- to high-risk patients is associated with bet-
teroutcomes.20-22Consequentevidencefromlargecohortstud-
ies across many countries shows a reduction in rates of death
followingacutecoronarysyndrome.1,2,23,24Yet therewerecon-
cerns that improvements inoutcomesweredue to a lower-risk
population. That is, the introduction of a higher-sensitivity
Figure 1. Use of Pharmacological Therapies at Hospital Discharge and Use of an Invasive Coronary Strategy
perMonth, 2003-2013
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Research Original Investigation Trends in Patient vs Therapeutic Strategies AssociatedWith NSTEMI Mortality, 2003-2013
1078 JAMA September 13, 2016 Volume 316, Number 10 (Reprinted) jama.com
Downloaded From: http://jama.jamanetwork.com/ by a University of Leeds User  on 09/30/2016
Copyright 2016 American Medical Association. All rights reserved.
troponin assay increases the diagnosis of type 1 acutemyocar-
dial infarction and has been associated with lower rates of
death.7,25-27 To date, however, studies reporting the decline
in acute coronary syndrome mortality have not identified
Figure 2. Crude All-CauseMortality at 30 Days, 180Days, and Full Follow-up (8.4 Years) perMonth
by GRACE Risk Score, 2003-2013
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a reduction in baseline risk of death.1 This study is one of the
first toourknowledge todescribeat scale thehighbutdecreas-
ing baseline acute coronary syndrome risk profile of patients
with NSTEMI as well as their increasingly comorbid status.
During the study period, there was a significant reduc-
tion in the proportion of patients with NSTEMI who were
given an initial diagnosis of chest pain of uncertain cause and
a corresponding increase in the number of patients with an
initial diagnosis of acute coronary syndrome or probable
acute myocardial infarction. It is possible that this was
related to the wider and earlier use of more sensitive cardiac
biomarkers.5 Earlier and more accurate diagnosis can lead
to more appropriate and timely treatment, including a risk-
determined invasive coronary strategy, with resultant
improved outcomes.5,28
Although the findings were consistent with mediation of
the reduction in mortality following NSTEMI by the use of an
invasive coronary strategy, the use of pharmacological thera-
pies prescribed at discharge offered little contribution to the
change in the full survival effects. However, these findings
should not be interpreted to indicate that medical therapies
have no role in management of NSTEMI. In the cohort, aspi-
rin, P2Y12 inhibitors, β-blockers, angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers, and stat-
ins each had a significant association with improved survival.
Themajority (>80%)ofpatients in thisNSTEMIcohortwere
at intermediate to high risk of death at 180 days. According to
international guidelines, those at and above intermediate risk
should receive an invasive coronary strategy; however, fewer
than half of those with NSTEMI underwent coronary angiog-
raphy. This finding is in keeping with the well-known risk-
treatment paradox whereby the highest frequency of treat-
ments were seen among patients in the lower risk category.29
Moreover, a series of randomized studies have shown that the
Table 3. Temporal Trends by Year in Overall Survival Between 2003 and 2013 for Unadjusted and Adjusted Flexible Parametric Survival Models
on the Proportional Odds ScaleWith 5 Degrees of FreedomAfterMultiple Imputationa
Model
Yearly Time Trend in Survival AIC and BIC Ranges Over 10 Imputed Data Sets
Hazard Ratio
(95% CI)b
Absolute Difference
in Hazard,
% (95% CI)c AIC Range BIC Range
Unadjusted yearly time trend 0.968 (0.966-0.971) −1.81 (−1.95 to −1.67) 771 858.74-771 858.74 771 926.22-771 926.22
Yearly time trend adjusted for
GRACE scored 0.975 (0.972-0.977) −0.18 (−0.21 to −0.16) 733 789.36-734 273.24 733 876.12-734 360.01
GRACE score, sex, and IMD 0.975 (0.973-0.978) −0.24 (−0.27 to −0.21) 732 794.96-733 291.51 732 891.37-733 387.91
GRACE score, sex, IMD, and comorbiditiese 0.973 (0.970-0.976) −0.44 (−0.49 to −0.39) 709 854.02-710 256.68 710 075.75-710 478.41
GRACE score, sex, IMD, comorbidities,
and pharmacological therapies at dischargef
0.972 (0.964-0.980) −0.53 (−0.70 to −0.36) 307 159.16-307 310.51 307 411.15-307 562.5
GRACE score, sex, IMD, comorbidities,
pharmacological therapies at discharge,
and invasive coronary strategyg
1.020 (1.012-1.029) 0.66 (0.38 to 0.93) 291 251.36-291 485.02 291 520.73-291 754.39
GRACE score, sex, IMD, comorbidities,
pharmacological therapies at discharge,
invasive coronary strategy,
and GRACE score × follow-up time
interaction (1 degree of freedom)h
1.020 (1.012-1.028) 0.59 (0.30 to 0.86) 291 349.97-291 478.24 291 628.02-291 756.29
GRACE score, sex, IMD, comorbidities,
pharmacological therapies at discharge,
invasive coronary strategy,
and GRACE score × follow-up time
interaction (2 degrees of freedom)
1.020 (1.012-1.029) 0.59 (0.33 to 0.86) 291 244.2-291 479.6i 291 530.95-291 746.35i
GRACE score, sex, IMD, comorbidities,
pharmacological therapies at discharge,
invasive coronary strategy,
and GRACE score × follow-up time
interaction (3 degrees of freedom)
1.020 (1.012-1.029) 0.59 (0.31 to 0.87) 291 245.6-291 481.05 291 541.03-291 776.49
GRACE score, sex, IMD, comorbidities,
pharmacological therapies at discharge,
invasive coronary strategy,
GRACE score × follow-up time
interaction (2 degrees of freedom),
and sex × invasive coronary strategy interaction
1.020 (1.008-1.025) 0.49 (0.23 to 0.75) 291 862.21-292 097.55 292 148.96-292 384.29
Abbreviations: AIC, Akaike information criterion; BIC, Bayesian information
criterion; GRACE, Global Registry of Acute Coronary Events; IMD, Index of
Multiple Deprivation.
a No. of deaths=37 236 (9.6%); 178 451.5 person-years of follow-up.
bHazard ratio of less than 1 indicates improved survival. All P<.001.
c Absolute difference in hazard per 100 patients between 2003 and 2013.
dAge, cardiac arrest, ST-segment deviation, elevated enzymes, systolic blood
pressure, heart rate, loop diuretic, and creatinine were not individually
included in themodeling process because they were all used in the calculation
of the GRACE risk score.
e Including history of diabetes, smoking, coronary heart disease, hypertension,
myocardial infarction, angina, peripheral vascular disease, cerebrovascular
disease, chronic obstructive pulmonary disease, chronic renal failure,
congestive heart failure, percutaneous coronary intervention, coronary artery
bypass graft surgery, and elevated cholesterol.
f Aspirin, β-blockers, statins, angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers, P2Y12 inhibitors, and aldosterone antagonists.
g Coronary angiography, percutaneous coronary intervention, or coronary
artery bypass graft surgery.
h Fitted as a time-varying covariate.
i Final chosenmodel that minimized the AIC/BIC.
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greatest benefit from an invasive coronary strategy was seen
among patients with higher-risk NSTEMI.30-32
To our knowledge, MINAP is the largest whole-country,
single-health-system,prospectiveobservational cohort of the
quality of care and clinical outcomes across the spectrum of
acute coronary syndrome. It is designed to be representative
of the management of acute coronary syndrome in a clinical
setting andhas standardized criteria for defining casemix and
treatments. However, there were limitations.
First, the studywas reliant on accurate recording of data.
Second, MINAP does not collect all cases of NSTEMI. Third,
missingdata couldhavebiased theestimates.However, an im-
putation strategy to minimize bias was implemented follow-
ing a previous comprehensive study of the nature of missing
MINAP data.33 Fourth, it is probable that other factors be-
yond the hospital stay (such as drug adherence and primary
care visits) may also have influenced survival. Although data
on primary care visits or drug adherence were not available,
the findings were consistent with mediation analysis show-
ing that only a small proportion of the change in survival was
statistically accounted for by referral for cardiac rehabilita-
tion—amultidimensional program that includes exercise pro-
grams, dietary advice, and smoking cessation advice if appro-
priate; drug adherence and psychological counseling; and
follow-up for up to 3 months after NSTEMI.
Fifth, all-cause mortality was studied because cause-
specific mortality data were not available. This is a limitation
because noncardiovascular deaths may not be attributable to
NSTEMIcare.However,cause-specificmortalitydatamightnot
always be reliable for cardiovascular-related causes of death.
Moreover, most deaths within 180 days of discharge after
NSTEMI would likely be cardiovascular related. Sixth,
in-hospital deaths were excluded, which could have resulted
in survivorship bias. Nonetheless, a sensitivity analysis re-
vealed that exclusion of these cases did not affect the conclu-
sions drawn. Seventh, the definition of an invasive coronary
strategy included coronary angiography,which is a diagnostic
procedure.EarlierworkusingMINAPdata investigated theas-
sociationbetweenuseofcoronaryangiographyandbetterout-
comes, wherebymore than 40%of patients with NSTEMI un-
derwent PCI.34 Eighth, the results from this study could have
beenbiasedbyselectionofcasesandmediatedbyfactorsother
than thosemodeled. Sensitivity analyses were undertaken to
quantify the potential bias and found that the resultant effect
sizeswereonlymodestlyreduced.However, theremaybesome
residual confounding from unmeasured factors. This study
found odds of death associated with use of an invasive coro-
nary strategy (odds of death, 0.54; 95%CI, 0.48-0.62) compa-
rablewith thatobserved inrandomizedclinical trialdata (odds
of death ormyocardial infarction, 0.68; 95%CI, 0.56-0.82).20
Ninth, this observational study cannot demonstrate causa-
tion, although adjustment was made for confounding factors
based on available information in the study data set and was
informed by external information from other studies.
Conclusions
Among patients hospitalized with NSTEMI in England and
Wales, improvements in all-cause survivalwere observed be-
tween 2003 and 2013 that were significantly associated with
use of an invasive treatment strategy and not entirely related
to a decline in baseline clinical risk or increased use of phar-
macological therapies.
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